Mitochondrial DNA Mutations as Natural Barcodes for Lineage Tracing of Murine Tumor Models. Cancer Res. 2023 03 02; 83(5):667-672.
View in:
PubMed
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). J Immunother Cancer. 2023 Mar; 11(3).
View in:
PubMed
YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma. J Clin Invest. 2023 Mar 01; 133(5).
View in:
PubMed
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 03 01; 4(2):150-169.
View in:
PubMed
Richter syndrome: Novel insights into the biology of transformation. Blood. 2023 Feb 09.
View in:
PubMed
Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci Immunol. 2023 02 03; 8(80):eabm6359.
View in:
PubMed
Enhancing CAR-T cell functionality in a patient-specific manner. Nat Commun. 2023 01 31; 14(1):506.
View in:
PubMed
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 Jan 27.
View in:
PubMed
The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia. Blood. 2023 01 26; 141(4):369-379.
View in:
PubMed
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia. Blood Adv. 2023 01 10; 7(1):145-158.
View in:
PubMed
Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169.
View in:
PubMed
Lower Incidence of Chronic GVHD Observed after Transplantation with Cryopreserved Unrelated Allogeneic Stem Cells. Blood Adv. 2023 Jan 03.
View in:
PubMed
Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. Clin Cancer Res. 2022 12 15; 28(24):5368-5382.
View in:
PubMed
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models. Blood Adv. 2022 Dec 07.
View in:
PubMed
Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022 11 24; 140(21):2193-2227.
View in:
PubMed
Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood. 2022 Nov 04.
View in:
PubMed
A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv. 2022 Oct 26.
View in:
PubMed
Spatial maps of T cell receptors and transcriptomes reveal distinct immune niches and interactions in the adaptive immune response. Immunity. 2022 10 11; 55(10):1940-1952.e5.
View in:
PubMed
Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. Sci Adv. 2022 Sep 16; 8(37):eabq5089.
View in:
PubMed
AML relapse after a TIGIT race. Blood. 2022 09 15; 140(11):1189-1191.
View in:
PubMed
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2022 09 15; 28(18):4045-4055.
View in:
PubMed
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022 09; 28(9):1848-1859.
View in:
PubMed
Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022 11; 54(11):1664-1674.
View in:
PubMed
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clin Cancer Res. 2022 08 02; 28(15):3356-3366.
View in:
PubMed
Cell-penetrating peptides enhance peptide vaccine accumulation and persistence in lymph nodes to drive immunogenicity. Proc Natl Acad Sci U S A. 2022 08 09; 119(32):e2204078119.
View in:
PubMed
Cancer vaccines: Building a bridge over troubled waters. Cell. 2022 07 21; 185(15):2770-2788.
View in:
PubMed
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. JCO Precis Oncol. 2022 07; 6:e2100413.
View in:
PubMed
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J Clin Invest. 2022 07 01; 132(13).
View in:
PubMed
Report of the First International Symposium on NUT Carcinoma. Clin Cancer Res. 2022 06 13; 28(12):2493-2505.
View in:
PubMed
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11).
View in:
PubMed
Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. Front Immunol. 2022; 13:859032.
View in:
PubMed
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature. 2022 05; 605(7910):532-538.
View in:
PubMed
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 2022 09 01; 40(25):2913-2923.
View in:
PubMed
Editorial overview: Vaccines: Reinvigorating therapeutic cancer vaccines. Curr Opin Immunol. 2022 06; 76:102176.
View in:
PubMed
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194.
View in:
PubMed
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood. 2022 04 07; 139(14):2252-2256.
View in:
PubMed
cyCombine allows for robust integration of single-cell cytometry datasets within and across technologies. Nat Commun. 2022 03 31; 13(1):1698.
View in:
PubMed
Tumor-Infiltrating T Cells - A Portrait. N Engl J Med. 2022 Mar 10; 386(10):992-994.
View in:
PubMed
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689.
View in:
PubMed
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 02; 23(2):279-291.
View in:
PubMed
Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022 01 04; 38(1):110190.
View in:
PubMed
Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics. Front Immunol. 2021; 12:788891.
View in:
PubMed
Understanding CLL biology through mouse models of human genetics. Blood. 2021 12 23; 138(25):2621-2631.
View in:
PubMed
Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective. Front Oncol. 2021; 11:790004.
View in:
PubMed
Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021 12 14; 5(23):5140-5149.
View in:
PubMed
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222.
View in:
PubMed
Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063.
View in:
PubMed
Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. Blood Adv. 2021 11 23; 5(22):4701-4709.
View in:
PubMed
Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 11 09; 37(6):109992.
View in:
PubMed
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Res. 2021 12 15; 81(24):6117-6130.
View in:
PubMed
Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022 02; 40(2):209-217.
View in:
PubMed
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nat Commun. 2021 09 13; 12(1):5395.
View in:
PubMed
Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples. Mol Cell Proteomics. 2021; 20:100133.
View in:
PubMed
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021 08 10; 5(15):2982-2986.
View in:
PubMed
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021 08; 596(7870):119-125.
View in:
PubMed
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. Clin Cancer Res. 2021 09 15; 27(18):5062-5071.
View in:
PubMed
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nat Cancer. 2021 07; 2(7):758-772.
View in:
PubMed
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
View in:
PubMed
60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy. Cancer Res. 2021 09 01; 81(17):4373-4384.
View in:
PubMed
Discovery of Candidate DNA Methylation Cancer Driver Genes. Cancer Discov. 2021 09; 11(9):2266-2281.
View in:
PubMed
Splice it up: Atypical transcripts to boost leukemia immunotherapy. Immunity. 2021 04 13; 54(4):608-610.
View in:
PubMed
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8.
View in:
PubMed
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell. 2021 03 08; 39(3):380-393.e8.
View in:
PubMed
Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
View in:
PubMed
COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871.
View in:
PubMed
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
View in:
PubMed
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
View in:
PubMed
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525.
View in:
PubMed
Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol. 2021 04; 18(4):199-214.
View in:
PubMed
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021 09 15; 27(18):5038-5048.
View in:
PubMed
Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discov. 2021 01; 2(1):13-18.
View in:
PubMed
Cancer and COVID-19: On the Quest for Effective Vaccines. Blood Cancer Discov. 2021 01; 2(1):13-18.
View in:
PubMed
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clin Cancer Res. 2021 09 15; 27(18):5049-5061.
View in:
PubMed
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discov. 2021 01; 2(1):54-69.
View in:
PubMed
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res. 2020 12; 8(12):1465-1469.
View in:
PubMed
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 03 01; 27(5):1371-1380.
View in:
PubMed
Frontiers in cancer immunotherapy-a symposium report. Ann N Y Acad Sci. 2021 04; 1489(1):30-47.
View in:
PubMed
High throughput single-cell detection of multiplex CRISPR-edited gene modifications. Genome Biol. 2020 10 20; 21(1):266.
View in:
PubMed
Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
View in:
PubMed
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in:
PubMed
Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Res. 2020 11 01; 80(21):4854-4867.
View in:
PubMed
Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat Biotechnol. 2021 04; 39(4):451-461.
View in:
PubMed
Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307.
View in:
PubMed
Delineating the evolutionary dynamics of cancer from theory to reality. Nat Cancer. 2020 06; 1(6):580-588.
View in:
PubMed
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
View in:
PubMed
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020 06; 26(6):909-918.
View in:
PubMed
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802.
View in:
PubMed
Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. J Clin Invest. 2020 04 01; 130(4):1595-1607.
View in:
PubMed
Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nat Commun. 2020 03 18; 11(1):1438.
View in:
PubMed
Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020 02; 10(2):185-197.
View in:
PubMed
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia. 2020 06; 34(6):1599-1612.
View in:
PubMed
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Sci Rep. 2020 01 20; 10(1):723.
View in:
PubMed
A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol. 2020 02; 38(2):199-209.
View in:
PubMed
Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. Clin Cancer Res. 2020 03 15; 26(6):1359-1371.
View in:
PubMed
Clonal dynamics in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):466-475.
View in:
PubMed
Clonal dynamics in chronic lymphocytic leukemia. Blood Adv. 2019 11 26; 3(22):3759-3769.
View in:
PubMed
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncol. 2019 Nov 01; 5(11):1631-1633.
View in:
PubMed
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13.
View in:
PubMed
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020 05; 105(5):1379-1390.
View in:
PubMed
RNase H-dependent PCR-enabled T-cell receptor sequencing for highly specific and efficient targeted sequencing of T-cell receptor mRNA for single-cell and repertoire analysis. Nat Protoc. 2019 08; 14(8):2571-2594.
View in:
PubMed
SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 09; 7(9):1485-1496.
View in:
PubMed
Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 06; 570(7762):474-479.
View in:
PubMed
Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia. Nature. 2019 05; 569(7757):576-580.
View in:
PubMed
Proceedings of the fourth international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2019 Aug; 30(8):799-811.
View in:
PubMed
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nat Commun. 2019 04 23; 10(1):1874.
View in:
PubMed
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. Leukemia. 2019 09; 33(9):2183-2194.
View in:
PubMed
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 2019 04; 9(4):476-481.
View in:
PubMed
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. Am J Hematol. 2019 04; 94(4):446-454.
View in:
PubMed
Dissecting CLL through high-dimensional single-cell technologies. Blood. 2019 03 28; 133(13):1446-1456.
View in:
PubMed
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell. 2019 02 11; 35(2):283-296.e5.
View in:
PubMed
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
View in:
PubMed
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in:
PubMed
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019 Mar; 68(3):421-432.
View in:
PubMed
Acquired mechanisms of immune escape in cancer following immunotherapy. Genome Med. 2018 11 22; 10(1):87.
View in:
PubMed
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19).
View in:
PubMed
A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921.
View in:
PubMed
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018 08 09; 174(4):1033.
View in:
PubMed
Immunotherapy for glioblastoma: going viral. Nat Med. 2018 08; 24(8):1094-1096.
View in:
PubMed
DeTiN: overcoming tumor-in-normal contamination. Nat Methods. 2018 07; 15(7):531-534.
View in:
PubMed
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 04 19; 173(3):624-633.e8.
View in:
PubMed
TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 2018; 7(7):e1442999.
View in:
PubMed
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
View in:
PubMed
Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov. 2018 06; 8(6):730-749.
View in:
PubMed
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017 12 19; 8(1):2185.
View in:
PubMed
Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018 03; 18(3):168-182.
View in:
PubMed
SnapShot: Chronic Lymphocytic Leukemia. Cancer Cell. 2017 11 13; 32(5):716-716.e1.
View in:
PubMed
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
View in:
PubMed
High-dimension single-cell analysis applied to cancer. Mol Aspects Med. 2018 02; 59:70-84.
View in:
PubMed
HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell. 2017 07 10; 32(1):1-3.
View in:
PubMed
An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
View in:
PubMed
Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res. 2017 08; 27(8):1300-1311.
View in:
PubMed
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med. 2017 Apr 03; 7(4).
View in:
PubMed
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer J. 2017 Mar/Apr; 23(2):115-124.
View in:
PubMed
Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity. 2017 02 21; 46(2):315-326.
View in:
PubMed
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204.
View in:
PubMed
Phosphatidylinositol 3-kinase d blockade increases genomic instability in B cells. Nature. 2017 02 23; 542(7642):489-493.
View in:
PubMed
Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017 Mar 20; 35(9):984-993.
View in:
PubMed
Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 02 09; 3:17008.
View in:
PubMed
Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017 01 19; 3:16096.
View in:
PubMed
Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations. Gynecol Oncol Rep. 2017 Feb; 19:42-45.
View in:
PubMed
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Nov 14; 30(5):750-763.
View in:
PubMed
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 10 18; 17(4):1206.
View in:
PubMed
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 09 12; 30(3):404-417.
View in:
PubMed
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in:
PubMed
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589.
View in:
PubMed
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16.
View in:
PubMed
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
View in:
PubMed
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25; 351(6280):1463-9.
View in:
PubMed
Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. Clin Cancer Res. 2016 Apr 01; 22(7):1547-9.
View in:
PubMed
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23.
View in:
PubMed
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015 Nov; 33(11):1152-8.
View in:
PubMed
Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22; 526(7574):525-30.
View in:
PubMed
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015 Oct 09; 350(6257):207-211.
View in:
PubMed
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 2015 Jul 23; 126(4):445-53.
View in:
PubMed
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
View in:
PubMed
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015 Apr; 15(4):201-15.
View in:
PubMed
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015 Jan 15; 160(1-2):48-61.
View in:
PubMed
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell. 2014 Dec 08; 26(6):813-825.
View in:
PubMed
Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition. J Clin Invest. 2014 Nov; 124(11):4681-3.
View in:
PubMed
Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology. 2014; 3:e29311.
View in:
PubMed
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
View in:
PubMed
Evolving understanding of the CLL genome. Semin Hematol. 2014 Jul; 51(3):177-87.
View in:
PubMed
Somatic mutation as a mechanism of Wnt/ß-catenin pathway activation in CLL. Blood. 2014 Aug 14; 124(7):1089-98.
View in:
PubMed
Vaccines and melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):559-69.
View in:
PubMed
Understanding anti-leukemia responses to donor lymphocyte infusion. Oncoimmunology. 2014; 3:e28187.
View in:
PubMed
HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun; 2(6):522-9.
View in:
PubMed
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21.
View in:
PubMed
Boosting leukemia-specific T cell responses in patients following stem cell transplantation. Oncoimmunology. 2013 Nov 01; 2(11):e26587.
View in:
PubMed
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45.
View in:
PubMed
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in:
PubMed
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
View in:
PubMed
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615.
View in:
PubMed
Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013; 5(5):47.
View in:
PubMed
SF3B1 mutations in chronic lymphocytic leukemia. Blood. 2013 Jun 06; 121(23):4627-34.
View in:
PubMed
Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol Res. 2013 Jul; 1(1):11-5.
View in:
PubMed
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
View in:
PubMed
An overview of the BioCreative 2012 Workshop Track III: interactive text mining task. Database (Oxford). 2013; 2013:bas056.
View in:
PubMed
BioCreative-2012 virtual issue. Database (Oxford). 2012; 2012:bas049.
View in:
PubMed
The eFIP system for text mining of protein interaction networks of phosphorylated proteins. Database (Oxford). 2012; 2012:bas044.
View in:
PubMed
Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. Nano Lett. 2012 Dec 12; 12(12):6498-504.
View in:
PubMed
CLL clonal heterogeneity: an ecology of competing subpopulations. Blood. 2012 Nov 15; 120(20):4117-8.
View in:
PubMed
Recent advances in biocuration: meeting report from the Fifth International Biocuration Conference. Database (Oxford). 2012; 2012:bas036.
View in:
PubMed
Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
View in:
PubMed
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9.
View in:
PubMed
CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 Feb; 62(2):347-57.
View in:
PubMed
Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin Cancer Res. 2012 Oct 15; 18(20):5761-72.
View in:
PubMed
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res. 2012 Jul 15; 18(14):3791-802.
View in:
PubMed
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in:
PubMed
Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines. Front Biosci (Landmark Ed). 2012 01 01; 17(2):635-55.
View in:
PubMed
Applications of next-generation sequencing to blood and marrow transplantation. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S151-60.
View in:
PubMed
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
View in:
PubMed
Components of the hematopoietic compartments in tumor stroma and tumor-bearing mice. PLoS One. 2011 Mar 25; 6(3):e18054.
View in:
PubMed
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
View in:
PubMed
Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells. Cancer Immunol Immunother. 2011 Jun; 60(6):857-67.
View in:
PubMed
Data processing and analysis for protein microarrays. Methods Mol Biol. 2011; 723:337-47.
View in:
PubMed
In mixed hematopoietic chimerism, the donor red cells win. Haematologica. 2011 Jan; 96(1):13-5.
View in:
PubMed
A coprecipitation-based validation methodology for interactions identified using protein microarrays. Methods Mol Biol. 2011; 723:239-54.
View in:
PubMed
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8.
View in:
PubMed
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39.
View in:
PubMed
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
View in:
PubMed
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
View in:
PubMed
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
View in:
PubMed
Revealing tumor immunity after hematopoietic stem cell transplantation. Clin Cancer Res. 2009 Jul 15; 15(14):4515-7.
View in:
PubMed
Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1270-8.
View in:
PubMed
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
View in:
PubMed
A concentration-dependent analysis method for high density protein microarrays. J Proteome Res. 2008 May; 7(5):2059-68.
View in:
PubMed
Allogeneic stem cell transplantation for the treatment of hemoglobinopathies. Stem Cell Transplantation for Hematologic Malignancies. 2008.
Immunologic targeting of the cancer stem cell. The Stem Book. 2008.
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7.
View in:
PubMed
Integration of bioinformatics resources for functional analysis of gene expression and proteomic data. Front Biosci. 2007 Sep 01; 12:5071-88.
View in:
PubMed
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
View in:
PubMed
Proteome informatics for cancer research: from molecules to clinic. Proteomics. 2007 Mar; 7(6):976-91.
View in:
PubMed
Target discovery using proteomic microarrays. BIOforum Europe. 2007; 11(10):20-22.
Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006; 90:133-73.
View in:
PubMed
Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45.
View in:
PubMed
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11.
View in:
PubMed
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
View in:
PubMed
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
View in:
PubMed
Inflammatory myopathy associated with imatinib mesylate therapy. J Clin Neuromuscul Dis. 2004 Mar; 5(3):119-21.
View in:
PubMed
Antibody response to BCMA in patients with multiple myeloma. 12th International Congress of Immunology and 4th Annual Conference of FOCIS. 2004; 355-63.
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol. 2004 Jan 01; 172(1):651-60.
View in:
PubMed
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
View in:
PubMed
Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003 Oct; 31(10):924-33.
View in:
PubMed
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5.
View in:
PubMed
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in:
PubMed
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522.
View in:
PubMed
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
View in:
PubMed
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
View in:
PubMed
Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
View in:
PubMed
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7.
View in:
PubMed
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7.
View in:
PubMed
The immunocompromised host. Samter's Immunologic Diseases,. 2001; 81:1067-1085.
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
View in:
PubMed
Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
View in:
PubMed
Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5.
View in:
PubMed
Cytokine gene expression in human cardiac allograft recipients. Transpl Immunol. 1994 Sep; 2(3):199-207.
View in:
PubMed
Cytokine gene expression in human lung transplant recipients. Transplantation. 1993 Oct; 56(4):956-61.
View in:
PubMed
Cytokine gene expression in rejecting cardiac allografts. Transplantation. 1992 Aug; 54(2):326-32.
View in:
PubMed
Murine memory B cells are multi-isotype expressors. Immunology. 1991 Jan; 72(1):48-55.
View in:
PubMed